Trial to Assess Chelation Therapy in Critical Limb Ischemia
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Prevention of major cardiovascular endpoints
研究概览
简要总结
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
详细描述
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
The study plans to enroll 50 patients with diabetes and critical limb ischemia (CLI) to prevent the major cardiovascular endpoints of major amputation, coronary revascularization, stroke, Myocardial Infarction (MI), or death (all-cause) during an average 1.25 years of follow-up. Patients will be randomly assigned to chelation or placebo with a 3:2 (30 active, 20 placebo) allocation ratio. Treatment will consist of 40 active or placebo infusions over 30 weeks. Active therapy will be the same edetate disodium-based infusion used safely and successfully in a previous published study, Trial to Assess Chelation Therapy (TACT). Baseline and post infusion urine metals will be collected. Following the final infusion, patients will be contacted quarterly until the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
double-blind
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 50 years
- •History of diabetes, defined as medical record evidence or patient report of currently using insulin or oral hypoglycemic agents, or with a history of fasting blood glucose measurement of 126 mg/dL or higher, or a history of HbA1c of 6.5% or higher.
- •Significant stenosis (≥ 75%) of two or more infra-popliteal arteries in the affected limb as verified by at least one imaging technique (angiography, magnetic resonance angiogram, coronary computed tomography angiogram, or doppler examination) within 6 months prior to enrollment;
- •History of CLI defined as moderate or high-risk infra-popliteal chronic critical limb ischemia (Rutherford Clinical Severity Score 4 or 5) defined as:
- •The presence of rest pain or non-healing ulceration or gangrene for at least 2 weeks plus documentation of severely compromised tissue perfusion:
- •If there is tissue loss, a resting ankle systolic pressure of ≤ 60 mmHg in the affected limb; or a resting toe systolic pressure of ≤ 40 mmHg or a tissue perfusion pressure (TPP) <40 mmHg.
- •If there is no tissue loss, a resting ankle pressure of ≤ 50 mmHg or resting toe systolic pressure of ≤ 30 mmHg or a tissue perfusion pressure (TPP) < 30 mmHg.
- •Not a candidate or a failed candidate for surgical or transcatheter revascularization;
- •Able to give informed consent.
排除标准
- •<7 days following lower extremity (infra-popliteal), carotid, or coronary revascularization.
- •Arterial insufficiency in the lower extremity as the result of a non-atherosclerotic disorder.
- •Subjects with evidence of active infection (e.g., cellulitis, osteomyelitis) or deep ulceration exposing bone or tendon or extensive heel ulceration
- •Subjects with extensive gangrene extending above the MT joint
- •Subjects in whom there is severe pain at rest uncontrollable with pain medications
- •Prior intravenous chelation therapy consisting of > 1 infusion within 5 years; if only 1 infusion took place, patient cannot be enrolled for at least 12 months after said infusion.
- •Oral chelation with an FDA-approved chelating agent within 2 years
- •Allergy to any components of the study drug
- •Planned leg revascularization within 1 month of enrollment
- •Symptomatic or clinically evident acute heart failure
- •Heart failure hospitalization within 3 months
- •Blood pressure >160/100
- •No venous access
- •eGFR < 30 mL/min per 1.73 m2 or lower (CKD stages 1-3) calculated with MDRD
- •Known or suspected acute kidney injury using prevalent KDIGO criteria45
- •Platelet count <100,000/mm3
- •Cigarette smoking within the last 3 months
- •Liver disease or Alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.0 times the upper limit of normal (this will require clearance by the Study PI)
- •Diseases of copper, iron, or calcium metabolism (other than osteopenia or osteoporosis, or simple iron deficiency). These require evaluation by the Study PI
- •Inability to tolerate the study-required fluid load
- •Other medical condition likely to affect patient survival within 3 years
- •Women of child-bearing potential
- •Any factor that suggests that the potential participant will not be able to adhere to the protocol.
研究组 & 干预措施
Placebo
Placebo infusion
干预措施: Placebo (Other)
Active
edetate disodium (EDTA)dff active infusion
干预措施: Edetate Disodium (Drug)
结局指标
主要结局
Prevention of major cardiovascular endpoints
时间窗: 3 years (average follow-up 1.25 years)
Major cardiovascular endpoints include: coronary revascularization, stroke, MI, death (all-cause), or major amputation
次要结局
- Amputations(3 years (average follow-up 1.25 years))
- Heart failure(3 years (average follow-up 1.25 years))
- Changes in Pain severity(3 years (average follow-up 1.25 years))
- Urine Metals(1 year)
- Changes in Quality of Life(3 years (average follow-up 1.25 years))
- Wound Severity(3 years (average follow-up 1.25 years))
- Changes in skin perfusion pressure in the ankle(3 years (average follow-up 1.25 years))
- Changes in skin perfusion pressure in the toe(3 years (average follow-up 1.25 years))
- Changes in PAD Quality of Life(3 years (average follow-up 1.25 years))
研究者
Gervasio Lamas, MD
Principal Investigator
Mt. Sinai Medical Center, Miami